Field-proven COVID-19 Telemedicine Solution for Hospitals

Deployable Within 48 Hours: Launched by Datos Leveraging Accumulated Experience in Monitoring Coronavirus Symptoms, Israeli Telehealth Company Releases Solution to Avoid Low-risk Patients Overwhelming Hospitals

As COVID-19 continues to spread, hospitals are expecting a surge in visitors to clinics and emergency rooms, which would result in a challenging additional burden on an already overstretched medical system.

Datos’s solution, easily implemented within 48 hours, is specifically designed to support hospitals across the world to mitigate such a situation by helping to keep suspected corona patients, and those infected but not requiring hospitalization, at home while still providing them with optimal care.

Hospitals and HMOs will be able to quickly deploy a robust and scalable COVID-19 telemedicine solution tailored to provide virtual services, including online symptom-checking tools and remote consultations with doctors, while simultaneously minimizing direct contact with those infected with the coronavirus.

The Datos COVID-19-specific telemedicine package is already in use at Sheba Medical Center, Israel’s largest hospital, and has begun implementations in U.S. hospital systems.

“Datos is providing an important solution for the US health care system to monitor COVID-19 remotely, easing the demand for inpatient-based monitoring at hospitals,” said Uri Bettesh, CEO of Datos Health. “The first solution of its kind, we are able to deploy it within 48 hours. It requires no additional resources as it seamlessly integrates with care teams’ existing workflows, providing crucial insights into patients being monitored outside the hospital at a fraction of the cost. Treating patients – who do not require hospitalization – out of emergency rooms could ensure that key resources are available for the most serious cases.”

The Datos COVID-19 solution offers:

  • For care teams, a fully configured COVID-19 dashboard that includes an overall view of all patients sorted according to the severity of coronavirus symptoms, the delivery of daily symptom checkout surveys, the seamless launch of virtual visits via video calls (including via text message, without requiring the Datos app), data-driven reminders (to measure temperature and complete surveys), messages and content.
  • For patients, a user-friendly mobile app (available on iOS and Android) for home hospitalized patients to manually enter their relevant vitals, including body temperature, BP and saturation. Patients will be asked to respond to two types of coronavirus surveys, an initial assessment followed by daily symptom status updates, sent automatically and then scored and correlated with monitored vitals to yield timely reminders, personalized messages and virtual doctor visits via video calls.

The solution additionally provides health systems with a private, HIPAA compliant, cloud-based interface of the Datos platform anywhere in the world. Optional extras include services delivered via a text message with links to web pages for reporting vitals management, survey distribution and video calls.

SourceDatos

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”